Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma.
Adenocarcinoma
/ metabolism
Aged
Area Under Curve
Biomarkers, Tumor
/ metabolism
Esophageal Neoplasms
/ metabolism
Esophagectomy
Esophagus
/ metabolism
Female
Granulocyte Colony-Stimulating Factor
/ metabolism
Humans
Logistic Models
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Staging
Odds Ratio
Prognosis
ROC Curve
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
04
2019
accepted:
24
06
2019
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
3
7
2020
Statut:
epublish
Résumé
To date no informative biomarkers exist to accurately predict presence of lymph node metastases (LNM) in esophageal adenocarcinoma (EAC). We studied the discriminative value of Olfactomedin 4 (OLFM4), an intestinal stem cell marker, in EAC. Patients who had undergone esophagectomy as single treatment modality for both advanced (pT2-4) and early (pT1b) adenocarcinoma of the esophagus or gastro-esophageal junction were selected for this study from an institutional database (Erasmus MC University Medical Center, Rotterdam, The Netherlands). Surgical resection specimens of 196 advanced and 44 early EAC were examined. OLFM4 expression was studied by immunohistochemistry and categorized as low (<30%) or high (> = 30%) expression. Low OLFM4 was associated with poor differentiation grade in both advanced (60% vs. 34.8%, p = 0.001) and early EAC (39.1% vs. 9.5%, p = 0.023). LNM were present in 161 (82.1%) of advanced and 9 (20.5%) of early EAC respectively. Low OLFM4 was independently associated with the presence of LNM in advanced EAC in multivariable analysis (OR 2.7; 95% CI, 1.16-6.41; p = 0.022), but not in early EAC (OR 2.1; 95% CI, 0.46-9.84; p = 0.338). However, the difference in association with LNM between advanced (OR 2.7; 95% CI, 1.18-6.34; p = 0.019) and early (OR 2.3; 95% CI, 0.47-11.13; p = 0.302) EAC was non-significant (p = 0.844), suggesting that the lack of significance in early EAC is due to the small number of patients in this group. OLFM4 was not of significance for the disease free and overall survival. Overall, low expression of intestinal stem cell marker OLFM4 was associated with the presence of LNM. Our study suggests that OLFM4 could be an informative marker with the potential to improve preoperative assessment in patients with EAC. Further studies are needed to confirm the value of OLFM4 as a biomarker for LNM.
Identifiants
pubmed: 31283789
doi: 10.1371/journal.pone.0219494
pii: PONE-D-19-10752
pmc: PMC6613772
doi:
Substances chimiques
Biomarkers, Tumor
0
OLFM4 protein, human
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0219494Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Radiol. 2017 Mar;88:56-60
pubmed: 28189209
Oncogene. 2016 Oct 6;35(40):5237-5247
pubmed: 26973250
Virchows Arch. 2015 Sep;467(3):285-94
pubmed: 26070873
Histopathology. 2007 Aug;51(2):157-65
pubmed: 17650212
PLoS One. 2015 May 21;10(5):e0127300
pubmed: 25996368
J Cancer Res Clin Oncol. 2011 Nov;137(11):1713-20
pubmed: 21904905
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
J Thorac Oncol. 2014 Aug;9(8):1202-6
pubmed: 25157774
Ann Thorac Surg. 2015 Jun;99(6):1879-85; discussion 1886
pubmed: 25929888
Surg Today. 2011 Sep;41(9):1190-5
pubmed: 21874413
World J Surg. 2013 Jan;37(1):147-55
pubmed: 23015224
BMB Rep. 2015 Nov;48(11):630-5
pubmed: 26303970
Am J Pathol. 2013 Oct;183(4):1329-38
pubmed: 24070418
Virchows Arch. 2018 Apr;472(4):519-531
pubmed: 29209757
Gastroenterology. 2009 Jul;137(1):15-7
pubmed: 19450592
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Cancer Metastasis Rev. 2010 Dec;29(4):761-75
pubmed: 20878207
J Thorac Cardiovasc Surg. 2014 Feb;147(2):765-71: Discussion 771-3
pubmed: 24314788
BMC Med. 2012 May 29;10:51
pubmed: 22642691
Biochemistry. 1991 Sep 24;30(38):9143-53
pubmed: 1892825
Endoscopy. 2010 Jun;42(6):456-61
pubmed: 20306385
Exp Ther Med. 2010 Jan;1(1):73-78
pubmed: 23136596
Clin Cancer Res. 2008 Feb 15;14(4):1041-9
pubmed: 18281536
Ann Transl Med. 2018 Feb;6(4):77
pubmed: 29666800
J Cell Mol Med. 2014 May;18(5):863-74
pubmed: 24495253
Biomed Pharmacother. 2017 Feb;86:67-73
pubmed: 27939521
Mol Carcinog. 2010 Mar;49(3):259-70
pubmed: 19908244
Cancer Res. 2004 Apr 1;64(7):2474-81
pubmed: 15059901
Best Pract Res Clin Gastroenterol. 2015 Feb;29(1):179-91
pubmed: 25743465
Exp Cell Res. 2006 Jun 10;312(10):1785-97
pubmed: 16566923
Dis Esophagus. 2018 Jan 1;31(1):1-6
pubmed: 29346598
Cancer Sci. 2007 Mar;98(3):334-40
pubmed: 17270022
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Gastroenterology. 2018 Jan;154(2):390-405
pubmed: 28780073
Gene. 2002 Jan 23;283(1-2):83-93
pubmed: 11867215
J Gastrointest Cancer. 2014 Sep;45(3):342-6
pubmed: 24788081
Carcinogenesis. 2011 Jul;32(7):986-94
pubmed: 21470957
Hepatogastroenterology. 2002 Jan-Feb;49(43):176-80
pubmed: 11941947
Br J Haematol. 2008 Nov;143(3):421-32
pubmed: 18764868
Oncogenesis. 2016 Jun 13;5(6):e234
pubmed: 27294866